


REMARKS

Currently claims 1-52, 54, and 60 are pending. Applicants amend the claims to remove unintentional duplication, place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,



Amy H. Fix
Attorney for Applicant
Registration No. 42,616

Date: 7 Sept. 2004
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8911
Facsimile: 919-483-7988